Therefore, our results are in accordance with many studies where genetic and pharmacological strategies to reduce NOX2 activity have been associated with attenuation of LV dysfunction, pathological remodeling, in models of diabetes [8,9,11,12], sepsis-induced cardiomyopathy [29], pressure overload [45], and in the aged heart [28]. This evidence concerns the gene CYBB and diabetes mellitus.